Evidence map›Paper›PMID 30535493›Full record

ArticleOncology reports2019

Genetic, epigenetic and transcriptional comparison of esophagus tumor‑associated and adjacent normal myofibroblasts.

Ildikó Huliák, László Bodai, Mátyás Czepán, Dávid Kovács, Anikó Szabó, László Tiszlavicz, György Lázár, Zoltán Rakonczay, Péter Hegyi, Imre Miklós Boros and 1 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ildikó HuliákDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
László BodaiDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
Mátyás CzepánFirst Department of Medicine, University of Szeged, Szeged H‑6720, Hungary.
Dávid KovácsDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
Anikó SzabóDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
László TiszlaviczDepartment of Pathology, University of Szeged, Szeged H‑6720, Hungary.
György LázárDepartment of Surgery, University of Szeged, Szeged H‑6720, Hungary.
Zoltán RakonczayFirst Department of Medicine, University of Szeged, Szeged H‑6720, Hungary.
Péter HegyiFirst Department of Medicine, University of Szeged, Szeged H‑6720, Hungary.
Imre Miklós BorosDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
Mónika KiricsiDepartment of Biochemistry and Molecular Biology, University of Szeged, Szeged H‑6726, Hungary.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myofibroblasts (MFs) are present in healthy tissues and are also key components of the tumor microenvironment. In the present study a comparative analysis of MFs obtained from various gastrointestinal tumor tissues and from tumor‑adjacent normal tissues of cancer patients was performed, with the aim to evaluate differences in MF morphology, gene expression profile and function. The goal was to correlate the observed morphological and functional variations with the underlying genetic and epigenetic backgrounds. The mutation frequency of MFs was assessed by next generation sequencing. The transcript levels of cancer‑specific genes were determined by TaqMan array and quantitative polymerase chain reaction. Epigenetic modifications were analyzed by immunocytochemistry and western blotting. The migratory capacity of MFs was assessed by scratch assay, whereas matrix metalloproteinase expression and activity were obtained by quantitative polymerase chain reaction and zymography. The results of the present study demonstrate that MFs were present in an increased number and with altered morphology in tumor samples compared with the healthy tissue. Although the detected number of mutations in tumor‑associated and normal tissue‑derived MFs did not differ markedly, shifts in the level of specific acetylated and methylated histone proteins, namely decreased levels of trimethylated H3K9 and acetylated H4K16 were demonstrated in tumor‑associated MFs. Transcript levels of several tumor‑specific genes involved in metastasis, regulation of cellular growth, apoptosis, as well as in hypoxia‑angiogenesis were altered in tumor‑derived MF cultures. Increased mRNA levels were obtained and activity of matrix metalloproteases in tumor‑derived MFs and these cells also exhibited a higher migratory capacity compared with the normal MFs. In summary, the results of the present study indicate that tumor‑associated MFs display an altered phenotype compared with healthy tissue derived counterparts. The results imply that epigenetic rather than genetic alterations are associated with the development of the distinct expressional and functional features, which define this MF phenotype in the tumor microenvironment.

Indexed as

Epigenesis, GeneticAcetylationAgedApoptosisCell ProliferationDNA MethylationEsophageal NeoplasmsEsophagusFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHistonesHumansImmunohistochemistryMaleHistonesRNA, Messenger

Identifiers

PMID30535493
PMCPMC6313073
OpenAlexW2903114690

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.